Ingenus Pharmac Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ingenus Pharmac (US): 9 reconciled FDA prescription therapies, $124.4M 2024 CMS Part D & Medicaid spend, and $7,103 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies9
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$124.4M
2024 Medicare Part D Spend$115.6M
2024 Medicaid Spend$8.8M
California HCAI SB 17 FilingsSpecialty launch notice ($7,103 intro WAC)